Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0028754 (obesity)
 124,988 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Plasma levels of estrone (E1), estradiol-17beta (E2), and estriol (E3), as well as follicle-stimulating hormone (FSH), luteinizing hormone (LH), and prolactin were measured in 30 control subjects and in 20 postmenopausal patients with adenocarcinoma of the endometrium. Within the sensitivity of the assay (5 to 10 pg.), no E3 was found. Mean levels of E1 and E2 in the patients with carcinoma (42.64+/-3.8 (S.E.M.) and 17.3+/-1.7 (S.E.M.) pg. per mililiter) were significantly higher than those measured in the control subjects (E1=26.97+/-2.4 (S.E.M.) pg. per mililiter, p less than 0.001; E2=12.08+/-1.2 (S.E.M.) pg. per milliliter, p less than 0.02). Effects of age, diabetic status, and obesity were taken into consideration. Significant differences in FSH and marginally significant differences in prolactin levels were observed between the two groups. Mean levels of FSH, LH, and prolactin in the control group and the group with adenocarcinoma, respectively, were as follows: FSH=152.3+/-7.0 (S.E.M.) versus 98.1+/-8.9 (S.E.M.) mI.U. per milliliter, p less than 0.001; LH=64.7+/-3.1 (S.E.M.) versus 66.5+/-5.2 mI.U. per milliliter, difference not significant; and prolactin=14.3+/-0.9 (S.E.M.) versus 17.8+/1.7 (S.E.M.) ng. per milliliter, p less than 0.06. These results, as well as previously reported alterations in human growth hormone secretion, suggest aberrations in hypothalamic function in endometrial carcinoma.
 ...
PMID:Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma. 98 36

The effects of bilateral lesions of the ventral noradrenergic bundle (VNA) were studied in male rats. In contrast to data reported by others, hyperphagia and obesity were not observed following VNA lesions. Indeed, except for a depression during the first three postoperative days, food intake (FI) of the VNA lesioned animals (VNAL) was normal. Interestingly, the body weight (BW) of the VNAL was significantly reduced compared to the controls, and a pair feeding study indicated that this depression of BW was not due to their FI. Computation of FI per metabolic size showed that the VNAL actually had a significantly increased FI compared to the controls. After a two day fast the VNAL lost more metabolic size than controls and upon refeeding they defended their pre-fast BW. The VNAL rats showed normal body composition and circulating glucose, insulin and prolactin. They had reduced free fatty acids, triglycerides, growth hormone and body length. The data suggest that the mesencephalon influences BW set point, some metabolites and possibly overall metabolism.
 ...
PMID:Mesencephalic lesions resulting in normophagia, reduced weight and altered metabolism. 99 50

Results are reported of an investigation of the hypothalamo-pituitary-ovarian-adrenal system in 51 women suffering of Itsenko-Cushing disease, primary obesity and menopausal syndrome. It was found that with onset of the menopause there occurs an increase of the concentration of lutropin, follitropin, testosterone and a reduction of the level of estradiol as in the control group. At the same time the level of prolactin and cortisol was increased as compared with the control group. Parlodel treatment in combination with specific drugs proved efficient.
 ...
PMID:[The treatment of the climacteric syndrome in women suffering from Itsenko-Cushing disease and primary obesity]. 136 24

Prolactin and aldosterone secretion and renin activity in the plasma were measured in the course of thyroliberin (TRH) test in women with various endocrine diseases, both connected with the water-salt metabolism disturbances and without these--with the idiopathic edemas (n = 11), hypothyrosis (n = 16), Stein-Leventhal'syndrome (n = 6), and obesity (n = 8). A reciprocal relationship between prolactin concentrations (a drastic elevation) and aldosterone levels (lowered) were revealed, as were universal responses of both the hormones to TRH administration in patients with various conditions. The authors come to a conclusion on the absence of a stimulating effect of prolactin on aldosterone secretion and plasma renin activity. They suggest an indirect contribution of prolactin to the regulation of the renin-aldosterone system, probably via dopaminergic mechanisms.
 ...
PMID:[Interrelationships between prolactin and the renin-aldosterone system in patients with various endocrine diseases]. 148 May 91

Cyclophosphamide and other alkylating agents suppress ovarian function in pre-menopausal women. However, endocrine details remain unknown regarding the influence of patients' age and obesity on CMF-induced hormonal changes. We studied changes in endocrine profile due to chemotherapy (CMF) in 70 pre-menopausal patients with axillary node positive, stage II and/or III breast carcinoma. Plasma levels of estrone (E1), estradiol (E2), androstenedione (A2), luteinizing hormone (LH), and prolactin (PRL) were determined on day 1 and 8 of each chemocycle for 12 cycles. After receiving therapy, 23% of the women continued to have regular menstrual cycles (non-amenorrheic group). In the remaining 77%, ovarian function was suppressed, as evidenced by the onset of amenorrhea within 0-11 months (amenorrheic group). The mean time to amenorrhea was 2.83 +/- 0.33 months (SE). The time required to develop amenorrhea inversely correlated to the patient's age. Both incidence of amenorrhea and time to amenorrhea remained unaffected by either patient's obesity or the timing of chemotherapy initiation in relation to menstrual cycle phase (progestational, follicular). Plasma hormone levels fluctuated widely in both groups during the first three chemocycles. During chemocycle months 4 to 10, in the amenorrheic group, plasma E1, E2, and P declined to their baseline levels with a concomitant rise in LH levels. At this time, E1, E2, and P levels were significantly lower in amenorrheics, despite menstrual cycle associated fluctuations in the non-amenorrheic group. Estrogens (E1 and E2) gradually declined further following the onset of amenorrhea in subsequent months. Further data analysis suggests that host age or obesity did not influence CMF-induced changes in the plasma endocrine profile.
 ...
PMID:Endocrine profile in breast cancer patients receiving chemotherapy. 155 88

The authors report a very rare case of pituitary adenoma producing both GH and ACTH. A 29-year-old female was admitted with obesity, amenorrhea, acromegaly, hirsutism, excessive pigmentation, acne, and diabetes mellitus. Computed tomography revealed an intrasellar tumor 16 mm in height, with a destroyed sellar floor. The blood concentrations of GH, ACTH and cortisol were increased (GH: 92 ng/ml, ACTH: 94 pg/ml, cortisol: 18.3 micrograms/dl). No diurnal variation in the amount of cortisol was observed. The urinary 17-OHCS was suppressed by 8 mg but not by 2 mg of dexamethasone. A subtotal adenomectomy was then performed through the transsphenoidal approach, which led to a sufficient reduction of both blood GH and ACTH (cortisol). Histologically the tumor was an acidophilic pituitary adenoma. Immunoperoxidase staining showed diffuse GH and sporadic ACTH producing cells, but failed to show any cells producing both hormones. The electron micrograms of neoplastic cells showed the ultrastructural characteristics of respective GH and ACTH cells. Another increase in both GH and cortisol, which occurred 19 months after the operation, has been controlled by bromocriptine administration. This case may be the first reported case of a pituitary adenoma producing both GH and ACTH, not accompanied by prolactin (PRL) hypersecretion, which has been fully confirmed endocrinologically and histopathologically.
 ...
PMID:A case of pituitary adenoma producing both growth hormone (GH) and adrenocorticotropic hormone (ACTH). 166 12

Hyperprolactinemia and prolactinoma in patients with long-term primary hypothyroidism have been recognized for decades. We report a case of 57-year-old female patient with lingual thyroid and cretinism who had a high serum prolactin level (greater than 200 ng/ml) and a pituitary tumor with suprasellar and parasellar extension. The tumor regressed to a size undetectable by CT scan after 2 years of thyroid hormone replacement therapy, but complete normalization of the hyperprolactinemia required additional bromocriptine therapy. This patient showed generalized short metacarpal and phalangeal bones, calcification of the basal ganglia and dentate nuclei bilaterally, and subcutaneous calcification at both gluteal regions, while serum calcium, phosphorus and c-PTH levels were all normal. Thus in addition to short stature, brachydactyly, a round face, and obesity, which are related to hypothyroidism, she also presented features uniquely mimicking the Albright's hereditary osteodystrophy seen in patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Since she had no family history of pseudohypoparathyroidism and had a normal level of Gs alpha protein on the membrane of the red blood cells, there is no evidence of pseudopseudohypoparathyroidism. The cause of the ectopic calcification remains unknown.
 ...
PMID:Intracranial calcification and brachydactyly mimicking Albright's hereditary osteodystrophy in an adult patient with lingual thyroid and prolactinoma-like lesion. 167 15

Prolactin reactions in response to insulin hypoglycemia and prolactin levels were examined in 20 obese women of reproductive age at various time of the day. In one group prolactin response to stimulation with insulin hypoglycemia was normal, in another group an increase in the level of prolactin was unnoticed. Both groups were compared with healthy controls. Two types of obesity (upper and lower) were investigated. A conclusion has been made that the absence of prolactin reaction in response to insulin hypoglycemia and an insufficient rise of prolactin at night are noted more frequently in women with upper type of obesity suggesting more profound endocrine derangements in them as compared to women with lower type obesity.
 ...
PMID:[Induced and spontaneous prolactin secretion in young, obese women]. 178

The goal pursued has been to analyze clinical observations and hormonal studies of patients with empty sella turcica (EST), in order to review this disorder and determine if it can be considered a real syndrome. Fifteen patients with EST (3 men and 12 women) and mean age of 45.6 +/- 17.9 years have been prospectively studied. In the hypothalamus-hypophysis study, reserves of thyrotropin (TSH), prolactin (PRL), gonadotropins (FSH and LH), growth hormone (GH), adrenocorticotropin (ACTH) and cortisol were assessed. In addition, thyroid hormones and, for men, testosterone, were determined. The pathogenic mechanism was explained in two cases (13.3%). We registered headache in 10 patients, obesity in 8, arterial hypertension in 2 and diabetes mellitus in 2. Multiparity antecedent was found in 2 cases. The hormonal study was abnormal in two cases (40%). Most common abnormalities were hyperprolactinemia (3 cases), deficit of gonadotropins (3 cases), without coexisting both of them in any case, and deficit of GH (2 cases). EST is frequently associated with endocrine disfunction, although clinical implications are rare. The absence of common clinical manifestations in most cases questions the EST as a real syndrome.
 ...
PMID:[Primary empty sella turcica: clinical aspects and hormonal study of 15 cases]. 179 Feb 77

The presence of vasoactive intestinal peptide (VIP) in the hypothalamus, anterior pituitary, and hypophyseal portal blood strongly suggests that VIP might be involved in the regulation of pituitary hormone secretion. To elucidate the relationship between VIP and the adrenergic system and its role in the mechanism of disturbed prolactin (PRL) and growth hormone (GH) release in obesity, serum VIP, GH, and PRL concentrations in response to alpha 2-adrenergic receptor agonist-clonidine were measured. Serum VIP levels were dramatically lower in obese as compared with non-obese patients, whereas clonidine did not alter VIP and PRL concentrations in either obese or non-obese patients. However, the response of GH to clonidine injection was blunted in obese patients. These results demonstrate an inhibited release of VIP in obesity. Whether a marked decrease of VIP may play a role in the mechanism of a disturbed release of GH and PRL remains to be explained.
 ...
PMID:A marked decrease of vasoactive intestinal peptide release in obese patients. 184 17


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>